Table 3.

The results of comparison of clinicopathologic characteristics in patients aged ≥80 years.

Variables	No. of patients (%)		P
	No chemotherapy (n = 60,127)	Chemotherapy (n = 8,441)
T stage			<0.0001
T1	8,434 (14.0)	364 (4.3)
T2	10,610 (17.6)	695 (8.2)
T3	33,037 (54.9)	5,496 (65.1)
T4	8,046 (13.4)	1,886 (22.3)
N stage			<0.0001
N0	42,144 (70.1)	2,177 (25.8)
N1	11,459 (19.1)	3,755 (44.5)
N2	6,524 (10.9)	2,509 (29.7)
M stage			<0.0001
M0	55,530 (92.4)	6,597 (78.2)
M1	4,597 (7.6)	1,844 (21.8)
Race			<0.0001
White	52,488 (87.3)	7,268 (86.1)
Black	3,917 (6.5)	547 (6.5)
Other	3,722 (6.2)	626 (7.4)
Gender			<0.0001
Male	24,482 (40.7)	3,989 (47.3)
Female	35,645 (59.3)	4,452 (52.7)
Year of diagnosis			<0.0001
2004–2007	22,687 (37.7)	2,896 (34.3)
2008–2011	20,374 (33.9)	2,895 (34.3)
2012–2015	17,066 (28.4)	2,650 (31.4)
Tumor site			<0.0001
Colon cancer	51,850 (86.2)	5,893 (69.8)
Rectal cancer	8,277 (13.8)	2,548 (30.2)
Grade			<0.0001
High/moderate	45,579 (75.8)	5,628 (66.7)
Poor/anaplastic	12,458 (20.7)	2,462 (29.2)
Unknown	2,090 (3.5)	351 (4.2)
Histotype			0.006
Adenocarcinoma	54,277 (90.3)	7,539 (89.3)
Mucinous/signet ring cell	5,850 (9.7)	902 (10.7)